November 7, 2016
Bayer seeks approval for its liver cancer drug
Bayer on Monday announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
November 7, 2016
Vertex's Phase 3 cystic fibrosis drug study shows improvement
Vertex Pharmaceuticals Incorporated today announced the results of a Phase 3 study of Orkambi (lumacaftor/ivacaftor) in children with cystic fibrosis…
November 7, 2016
Orphan drugs make 35% Horizon's sale in Q3 2016
Horizon Pharma has announced its third-quarter 2016 financial results on Monday.
November 7, 2016
Neovacs enroles first U.S. patient in its Phase IIb study of IFNalpha Kinoid in lupus.
Neovacs, a player in active immunotherapy for the treatment of autoimmune diseases, has enroled the first U.S. patient in its international Phase IIb clinical study of IFNalpha Kinoid in lupus.
November 7, 2016
Amryt gets FDA's designation for orphan drug to treat acromegaly
Amryt has received orphan drug designation from U.S. Food and Drug Administration (FDA) for its drug compound…
November 7, 2016
Richard Jones goes from Shield Therapeutics to Mereo as CFO
Mereo BioPharma has appointed Richard CM Jones as Chief Financial Officer
November 7, 2016
Celyad's NKR phase I trial shows encouraging results
The first data analysis of the NKR-2 Phase I trial, run by the Belgia’s biopharmaceutical company Celyad, shows encouraging results
November 7, 2016
Avacta names Prof. Gerard Evans to its Scientific Advisory Board
Professor Gerard Evan, FRS, has joined Scientific Advisory Board of Avacta Group, the developer of Affimer biotherapeutics and research reagents.
November 4, 2016
Genfit gets FDA’s IND clearance for PBC drug to go on with phase 2 study
The primary objective is to determine the effect of daily oral administration of elafibranor on serum alkaline phosphatase (ALP) in these patients, based on relative change versus placebo.
November 4, 2016
Lartruvo-soft tissue sarcoma drug to sell in U.S.
FDA granted accelerated approval to Lartruvo (olaratumab) injection, in combination with doxorubicin, for the treatment of adult patients…